TY - JOUR
T1 - Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
AU - Arudra, Krishna
AU - Patel, Ravi
AU - Tetzlaff, Michael T.
AU - Hymes, Sharon
AU - Subbiah, Vivek
AU - Meric-Bernstam, Funda
AU - Torres-Cabala, Carlos
AU - Aung, Phyu P.
AU - Nagarajan, Priyadharsini
AU - Diab, Adi
AU - Prieto, Victor G.
AU - Nelson, Kelly
AU - Curry, Jonathan L.
N1 - Publisher Copyright:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2018/10
Y1 - 2018/10
N2 - Small-molecule inhibitors (nibs) have revolutionized cancer therapy with the emergence of clinically efficacious treatment for advanced-stage malignancies. Fibroblast growth factor receptor (FGFR) inhibitors have shown therapeutic efficacy in malignancies with molecular-genetic alterations in the FGFR/fibroblast growth factor pathway. In a phase 1 clinical trial, erdafitinib, a pan FGFR inhibitor, was well tolerated with a manageable toxicity profile. Hyperphosphatemia was a frequent adverse event in patients treated with erdafitinib; however, no serious complications were observed with this therapy. Here, we report the development of calcinosis cutis dermatologic toxicity in a patient with hyperphosphatemia while treated with a novel selective FGFR inhibitor, INCB 54828-101. Awareness of this form of dermatologic toxicity from an FGFR inhibitor will be important for close monitoring of serum levels of phosphate, FGF23, vitamin D, and calcitriol, the management of adverse serum chemistry with chelators, and treatment decisions to either reduce dose or withhold FGFR inhibitor.
AB - Small-molecule inhibitors (nibs) have revolutionized cancer therapy with the emergence of clinically efficacious treatment for advanced-stage malignancies. Fibroblast growth factor receptor (FGFR) inhibitors have shown therapeutic efficacy in malignancies with molecular-genetic alterations in the FGFR/fibroblast growth factor pathway. In a phase 1 clinical trial, erdafitinib, a pan FGFR inhibitor, was well tolerated with a manageable toxicity profile. Hyperphosphatemia was a frequent adverse event in patients treated with erdafitinib; however, no serious complications were observed with this therapy. Here, we report the development of calcinosis cutis dermatologic toxicity in a patient with hyperphosphatemia while treated with a novel selective FGFR inhibitor, INCB 54828-101. Awareness of this form of dermatologic toxicity from an FGFR inhibitor will be important for close monitoring of serum levels of phosphate, FGF23, vitamin D, and calcitriol, the management of adverse serum chemistry with chelators, and treatment decisions to either reduce dose or withhold FGFR inhibitor.
KW - FGFR inhibitor
KW - calcinosis cutis
KW - dermatologic toxicity
UR - http://www.scopus.com/inward/record.url?scp=85052456108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052456108&partnerID=8YFLogxK
U2 - 10.1111/cup.13319
DO - 10.1111/cup.13319
M3 - Article
C2 - 30021048
AN - SCOPUS:85052456108
SN - 0303-6987
VL - 45
SP - 786
EP - 790
JO - Journal of cutaneous pathology
JF - Journal of cutaneous pathology
IS - 10
ER -